

Psychopharmacological Drugs Advisory Committee
Questions: February 14, 2001

NDA 21-253: Zyprexa® (olanzapine IM, Eli Lilly, Inc.)

Questions: February 15, 2001
NDA 20-919, Zeldox™ (ziprasidone mesylate IM, Pfizer, Inc.)

A. General Discussion Questions (before the review of either specific claim)

Effectiveness Data of Oral formulations and Relationship to IM

1. Are effectiveness data needed to support the approval of a parenteral formulation of an antipsychotic for IM use, or is it sufficient to rely on the efficacy data available for the orally administered immediate release formulation?

Effectiveness Data and Relationship to Clinical Symptoms

2. If effectiveness data are needed, what should be the clinical target that is the focus of the required effectiveness studies?

Effectiveness Data and Relationship to Schizophrenia

3. If effectiveness data are needed, should the focus be on schizophrenia (the approved indication for the oral formulation) or on some other clinical findings present during an acute episode of illness that are deemed to require the use of IM medication?

3.a If schizophrenia is considered to be the appropriate clinical target for the development of IM formulations of antipsychotic drug products, what study designs would be optimal to support a claim for these products?

Effectiveness Data and Relationship to “Agitation”

4. Is “agitation” an acceptable clinical target for the development of IM antipsychotic drug products?

4.a. If so, how should “agitation” be defined?

4.b. What outcome measures are optimal for the assessment of “agitation?”

4.c. What study designs are optimal for the study of “agitation?”

4.d. Is it worthwhile distinguishing between what might be considered “acute agitation” and “chronic agitation?”

4.e. Is “agitation” a phenomenon that is specific to different disease states or can this be considered a nonspecific symptom that occurs in identical form in association with different disease states?

4.f. If “agitation” can be considered a nonspecific symptom, is it necessary to study it in different disease models in order to gain a claim?

-

4. g. If so, in what disease models should it be studied?

Psychopharmacological Drugs Advisory Committee

Questions: February 14, 2001

NDA 21-253: Zyprexa® (olanzapine IM, Eli Lilly, Inc.)

Questions: February 15, 2001

NDA 20-919, Zeldox™ (ziprasidone mesylate IM, Pfizer, Inc.)

B. Questions Specific to Safety and Efficacy for each of the two NDAs.

1. Has the sponsor provided evidence from more than one adequate and well-controlled clinical investigation that supports the conclusion that (olanzapine IM/ziprasidone IM) is effective for the treatment of agitation?
2. Has the sponsor provided evidence that (olanzapine IM/ziprasidone IM) is safe when used in the treatment of agitation?